Glucagon-Like Peptide-1 Based Therapies and the Risk of Severe Gastrointestinal Motility Adverse Events: A Cohort Study

By afschroeder • June 5, 2026

Alkabbani W, Crisafulli S, Paik JM, Tavakkoli A, Bykov K, Glynn RJ, Wexler DJ, Patorno E. Glucagon-Like Peptide-1 Based Therapies and the Risk of Severe Gastrointestinal Motility Adverse Events: A Cohort Study. Diabetes Obes Metab. 2026 Jun 4. doi: 10.1111/dom.70963. Epub ahead of print. PMID: 42244136.

Tags: antidiabetic drug, Cohort study, General Internal Medicine, GLP‐1 analogue, pharmaco‐epidemiology, Publications, real‐world evidence

Investments in Childhood Community Resources and Subsequent Adult Health Outcomes

La Charite J, Dudovitz R, Choi K, Chen K, Jackson NJ, Nuckols T, Sastry N, Schickedanz A, Wong MD, Zimmerman FJ. Investments in Childhood Community[...]

Creation of a Multidisciplinary Cycling Medicine Clinic: Analysis of the First 9 Years

Searle O, Rice S, Fowler C, Kotler DH. Creation of a Multidisciplinary Cycling Medicine Clinic: Analysis of the First 9 Years. Curr Sports Med Rep.[...]

Late Recognition of Glucose-6-Phosphate Dehydrogenase Deficiency in a 70-Year-Old Man: A Case Report

Huynh J, Eisenbud L, Gutierrez R, Chuang FL, Dichter D. Late Recognition of Glucose-6-Phosphate Dehydrogenase Deficiency in a 70-Year-Old Man: A Case Report. Cureus. 2026[...]